Alexa Fluor® 594 anti-human CD326 (EpCAM) Anti-上海雅吉生物科技有限公司

规格	价格	库存
100µg	￥ 3456	1

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

DU.4475 breast carcinoma

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 594 under optimal conditions.

Concentration

0.5 mg/mL

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

IHC-P - Quality tested
ICC?- Verified
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, the suggested use of this reagent is 5.0 - 10 ?g per mL.?For?immunocytochemistry, a concentration range of 2.5 - 10 μg per mL?is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 594 has an excitation maximum of 590 nm, and a maximum emission of 617 nm.

Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses

Excitation Laser

Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the revelant formats) include: immunofluorescence,?immunohistochemistry³, and spatial biology (IBEX)^4,5.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References (PubMed link indicates BioLegend citation)

Lammers R, et al. 2002. Exp. Hematol. 30:537.
Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed
Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody (IHC)
Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed

Product Citations

Kenerson HL, et al. 2021. STAR Protocols. 2(2):100574. PubMed
Roy J, et al. 2020. Theranostics. 10:5778. PubMed
Sharma A, et al. 2020. Biotechnol Bioeng. 117:2540. PubMed
Hough KP, et al. 2020. Methods. 27:177. PubMed
Kure K, et al. 2020. Oncol Lett. 19:2286. PubMed

RRID

AB_2563209 (BioLegend Cat. No. 324228)

Antigen Details

Structure: Type I transmembrane protein, contains six disulfide bridges, one THYRO domain, approximate molecular weight 40 kD.
Distribution: Highly expressed in bone marrow, colon, lung, and most normal epithelial cells. Also highly expressed on carcinomas of gastrointestinal origin. Expressed during early erythrogenesis.
Function: Homotypic calcium-independent cell adhesion. CD326 is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation.
Modification: Glycosylated.
Cell Type: Embryonic Stem Cells, Epithelial cells
Biology Area: Cell Biology, Immunology, Stem Cells
Molecular Family: Adhesion Molecules, CD Molecules
Antigen References: 1. Strnad J, et al. 1989. Cancer Res. 49:314.
2. Munz M, et al. 2004. Oncogene 23:5748.
3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.
Gene ID: 4072 View all products for this Gene ID
UniProt: View information about CD326 on UniProt.org

上海细胞库

原代细胞

细胞培养

细胞服务

酶联试剂盒

生化试剂盒

PCR试剂盒

抗体蛋白

试剂耗材

首页 > 抗体蛋白 > 抗体

产品详情

Product Details

Antigen Details

联系我们